Log in
Log in
Or log in with
GoogleGoogle
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Pascal Soriot
Birthday : 04/12/1959
Public asset : 68,678,123 USD
Country of residence : Unknown
Linked companies : AstraZeneca PLC

Biography of Pascal Soriot 
Pascal Claude Roland Soriot (born 23 May 1959) is the Chief Executive of the Anglo-Swedish pharmaceutical multinational company AstraZeneca, and has been since October 2012.

Early life
He studied Veterinary Medicine at university (╔cole nationale vÚtÚrinaire d'Alfort at Maisons-Alfort in south-east Paris). as a salesman, where he lived in Australia.

AstraZeneca
On 28 August 2012 he was named as the new Chief Executive of AstraZeneca, the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012.

Personal life
He is married with two children and one grandchild.



Source @ Wikipedia


Current positions of Pascal Soriot 
Holdings of Pascal Soriot 
Pascal Soriot : Personal Network 
Most Read News 
09/28Biden to warn of threat to democracy from Trump, honor McCain
RE
09/21Rupert Murdoch steps down as chairman of Fox, News Corp
RE
09/28Elon Musk wades into US immigration debate at Texas-Mexico border
RE
09/22The FTSE 100 Closed Up as UK Retail Sales, Consumer Confidence Data Offers Economic Hope
DJ
09/18Sorrell's ad group S4 Capital lowers outlook
RE
09/21Thailand's new PM meets Tesla chief Musk in New York
RE
09/26North American Morning Briefing: Yield Surge Continues to Knock Stocks
DJ
09/18Square CEO Alyssa Henry to Step Down, Be Succeeded by Jack Dorsey
DJ
09/18Prosus, Naspers CEO Bob Van Dijk Steps Down; Ervin Tu Named Interim
DJ
09/19News Highlights: Top Company News of the Day
DJ
More news


© 2023 People and Ownership :   
Pascal Soriot : Connections 


Latest news about Pascal Soriot 
09/11Astrazeneca spokesperson says they would make a statement if the…
RE
09/11AstraZeneca seeks to calm CEO speculation after shares drop
RE
09/11AstraZeneca shares fall 3.6% to 7-1/2 week low
RE
09/11AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
RE
09/11Miners boost FTSE 100 on China optimism; Vistry jumps
RE
More news

The best tools reserved for subscribers to boost the performance of your investments!Optimize my profits
Optimize my profits